Argon Laser Peripheral Iridoplasty for Primary XXXX : A Randomized Controlled Trial.

@entity1 @entity726 @entity3009 @entity1897 @entity2790 @entity2747
PURPOSE: To determine the effectiveness of @entity1897 ( @entity1897 ) in primary angle closure (PAC) and primary @entity2747 (PACG). DESIGN: Randomized controlled trial. @entity1 : Eighty PAC or PACG subjects who underwent laser iridotomy (LI) and had at least 180   of persistent appositional angle closure and @entity2790 ( @entity2790 ) of more than 21 mmHg were enrolled. METHODS: Subjects were randomized to receive either 360   @entity1897 (Visulas 532s; Carl Zeiss Meditec, Jena, Germany) or medical therapy (Travoprost 0.004%; Alcon-Couvreur, Puurs, Antwerp, Belgium). Repeat @entity1897 was performed if the @entity2790 reduction was less than 20% from baseline along with inadequate angle widening at the month 1 or month 3 visit. Intraocular pressure was controlled with systematic addition of medications when required. MAIN OUTCOME MEASURES: The primary outcome measure was success rates after @entity1897 at 1 year. Complete success was defined as an @entity2790 of 21 mmHg or less without medication, and qualified success was defined as an @entity2790 of 21 mmHg or less with medication. Failure was defined as an @entity2790 more than 21 mmHg despite additional medications or requiring @entity726 surgery. RESULTS: Forty subjects (51 eyes) were randomized to @entity1897 and 40 subjects (55 eyes) were randomized to medical therapy. Complete success ( @entity2790  <=21 mmHg without medication) was achieved in 35.0% eyes of the @entity1897 group compared with 85.0% of eyes in the @entity3009 analog (PGA) group (P < 0.001), and qualified success ( @entity2790  <=21 mmHg with medication) was achieved in 35.0% and 7.5%, respectively (P  = 0.003). The @entity2790 decreased by 4.9 mmHg (95% confidence interval [CI], 3.5-6.3 mmHg) in the @entity1897 group (P < 0.001) and by 6.1 mmHg (95% CI, 5.1-7.1 mmHg) in the medication group (P < 0.001). A failure rate of 30.0% was noted in the @entity1897 group compared with 7.5% in the medication group (P  = 0.01). No treatment-related complications were recorded in either group. CONCLUSIONS: After 1 year, @entity1897 was associated with higher failure rates and lower @entity2790 reduction compared  with PGA therapy in eyes with persistent appositional angle closure and raised @entity2790 after LI.
